Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

SAN DIEGO, April 11, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its target price lifted by Canaccord Genuity Group from $45.00 to $47.00 in a research note issued to investors on Thursday morning ...

Canaccord analyst Edward Nash raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

Ratings for Travere Therapeutics TVTX were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming ...

On Thursday, Cantor Fitzgerald maintained an Overweight rating on Travere Therapeutics (NASDAQ:TVTX) shares, with a focus on the potential approval and market uptake of their drug candidate Filspari.